Dynavax Technologies Corporation  

(Public, NASDAQ:DVAX)   Watch this stock  
Find more results for DVAX
15.94
+1.16 (7.85%)
Real-time:   3:30PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.93 - 15.94
52 week 12.84 - 32.49
Open 14.93
Vol / Avg. 462,865.00/557,612.00
Mkt cap 604.62M
P/E     -
Div/yield     -
EPS -2.84
Shares 38.50M
Beta 2.47
Inst. own 89%
Aug 5, 2016
Q2 2016 Dynavax Technologies Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 15, 2016
Dynavax Technologies Corp at William Blair Growth Stock Conference
May 31, 2016
Dynavax Technologies Corp Annual Shareholders Meeting
May 26, 2016
Dynavax Technologies Corp Annual Shareholders Meeting (Estimated)
May 25, 2016
Dynavax Technologies Corp at UBS Global Healthcare Conference
May 9, 2016
Q1 2016 Dynavax Technologies Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -2868.68% -2636.89%
Operating margin -2897.45% -2635.65%
EBITD margin - -2517.33%
Return on average assets -53.36% -60.18%
Return on average equity -61.67% -74.28%
Employees 234 -
CDP Score - -

Address

2929 7th St Ste 100
BERKELEY, CA 94710-2753
United States - Map
+1-510-8485100 (Phone)
+1-510-8481327 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company's lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Officers and directors

Arnold L. Oronsky Ph.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Eddie Gray Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Michael S. Ostrach Principal Financial Officer, Vice President, General Counsel, Chief Business Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert L. Coffman Ph.D. Senior Vice President, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
David F. Novack Senior Vice President - Operations and Quality
Age: 53
Bio & Compensation  - Reuters
David Louis Johnson Chief Accounting Officer, Vice President
Age: 57
Bio & Compensation  - Reuters
Robert Janssen M.D. Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 58
Bio & Compensation  - Reuters
Natale S. Ricciardi Director
Age: 67
Bio & Compensation  - Reuters
Francis R. Cano Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters